As posted on the House Rules Committee website on September 18, 2019.
Division A of H.R. 4378 would provide for the continuation, through November 21, 2019, of the appropriations and authorities contained in the 12 annual appropriation acts for 2019. Table 1 compiles CBO’s estimates of discretionary budget authority for 2020 under that division; those amounts are annualized—that is, estimated as if appropriations were provided for the entire fiscal year. In 2020 most discretionary budget authority is subject to limits (or caps) established by the Budget Control Act of 2011 (P.L. 112-25), as modified. Separate caps exist for defense funding (in the law, revised security ), which is budget function 050, and for nondefense funding (revised nonsecurity ), which encompasses all other budget functions. The Budget Control Act also provides for certain adjustments to those caps. This table delineates CBO’s annualized estimates of funding that would be constrained by the 2020 caps on defense and nondefense funding and the amounts that would result in adjustments to those caps.
Table 2 displays CBO’s estimate of changes in direct spending under division B of H.R. 4378, which would extend certain health programs. The division also would prohibit drug manufacturers from lowering the average manufacturer price (AMP) of brand-name drugs by including authorized generics in the AMP calculation. Consistent with the language in section 701, and at the direction of the House and Senate Committees on the Budget, division B is considered to be authorizing legislation rather than appropriation legislation.